Rocket Pharmaceuticals Inc.’s (RCKT) investigational gene therapy KRESLADI, proposed for severe Leukocyte Adhesion Deficiency-I awaits the FDA decision on June 30, 2024.Severe Leukocyte Adhesion Deficiency-I (LAD-I) is a rare, autosomal recessive pediatric disease caused by mutations in the ITGB2 gene.LAD-I affects about 800 to 1,000 people in the U.S. and Europe. Currently, allogeneic hematopoietic stem cell transplant remains the sole potential curative option, albeit fraught with significant morbidity and mortality risks.RCKT closed Wednesday’s trading at $20.66, down 1.34%.